EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Conditions

• Breast Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ctDNA MRD test — DIAGNOSTIC_TEST
  Blood and tissue samples will be collected for the ctDNA MRD test

Study Details

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

Key Dates

Start date

Jun 7, 2024

Status verified

Jan 2026

Primary completion

Apr 30, 2030

Completion

Apr 30, 2030

Study Design

Enrollment

1,800 participants (estimated)

Arms

• Arm: Participants with High Risk Early Breast Cancer
  Participants with High Risk Early Breast Cancer

Primary Outcome Measure

Core biopsy tissue evaluability rate [ Time Frame: 3 years ]

Central Contacts

• NSABP Department of Site and Study Management Department of Site and Study Management
  1-800-270-3165
  [email protected]

Locations (53)

Find similar trials in Anchorage, AK

Related Studies

• Collection of Blood From Patients With Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Harvesting Cells for Experimental Cancer Treatments
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
• High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
  Recruiting · Carol Fabian, MD · Kansas City, Kansas
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland